Welcome to our dedicated page for Becton Dickinson & news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton Dickinson & stock.
Becton, Dickinson and Company reports developments for a global medical technology business organized around medical essentials, connected care, biopharma systems and interventional products. Company news commonly covers fiscal results, guidance, dividends, share repurchases, debt retirement, executive appointments and strategy updates following the completed separation of the Biosciences and Diagnostic Solutions business.
BD updates also include product and customer developments across its care-delivery platforms. Recent themes include the BD® CentroVena One™ Insertion System for central venous catheter placement, BD Pyxis™ Pro medication dispensing technologies, BD Alaris™ Infusion Systems, vascular access products, medication management, patient-safety workflows and partnerships with health systems.
BD (Becton, Dickinson and Company) will invest €165 million ($200 million USD) to establish a high-tech manufacturing facility in Zaragoza, Spain, projected to create 600 jobs by 2030. The construction is set to start in late 2021, contributing to BD's 2025 growth strategy of expanding pre-filled syringe manufacturing capacity. The new plant will be fully digital, aligning with sustainability standards, and aims to support COVID-19 vaccination efforts and other biologic drug deliveries in the European market.
BD (Becton, Dickinson and Company) announced a significant milestone with the CE marking of the industry's first self-collection HPV screening assay. This advancement allows laboratories to process samples collected by patients themselves using BD's Onclarity™ HPV Assay, enhancing accessibility for women hesitant to undergo clinical screening. Approximately 61,000 women are diagnosed with cervical cancer in Europe annually, highlighting an urgent need for improved screening strategies, especially post-COVID-19. The assay detects 14 high-risk HPV types, contributing to more effective cervical cancer prevention efforts.
BD (Becton, Dickinson and Company) reported Q2 fiscal 2021 revenues of $4.9 billion, a 15.4% year-over-year increase, driven by $480 million in COVID-19 diagnostic sales. Diluted EPS rose 77.4% to $0.94, with adjusted EPS of $3.19 reflecting a 25.1% increase. The company maintains an outlook for 12%-14% revenue growth and $12.75-$12.85 adjusted EPS for the full year. Key milestones include the 510(k) submission for the BD Alaris™ System and a planned spin-off of its diabetes business.
BD has announced a plan to spin off its Diabetes Care business into an independent company, referred to as NewCo. This strategic move is aimed at enhancing growth and allowing both entities to focus better on their core markets. In fiscal 2020, the Diabetes Care business generated nearly $1.1 billion in revenue. The spinoff is expected to be tax-free for U.S. federal income tax purposes and is anticipated to be completed in the first half of 2022, subject to approvals. This decision reflects BD's commitment to its 2025 strategy aimed at maximizing value for stakeholders.
BD (Becton, Dickinson and Company) has announced its participation in several virtual investor healthcare conferences in May 2021. Key events include the Bank of America Securities 2021 Virtual Healthcare Conference on May 12 at 2:45 PM ET and the UBS Global Healthcare Virtual Conference on May 24 at 2:00 PM ET. Presentations will be available via live webcasts on the BD corporate website, with replays accessible for at least seven days post-event. BD, a global leader in medical technology, focuses on advancing healthcare through innovation.
BD (Becton, Dickinson and Company) has initiated enrollment in the post-market CONNECT-AV study for the WavelinQ™ EndoAVF System, aimed at evaluating its effectiveness in hemodialysis access. This prospective study will track 280 patients over 24 months, measuring primary endpoints such as successful cannulation rates and device safety. The global hemodialysis patient population relies heavily on AV fistulas, making this research critical. BD's innovative approach provides a minimally invasive option compared to traditional surgical methods, enhancing patient care.
BD (Becton, Dickinson and Company) has appointed Elizabeth McCombs as executive vice president and chief technology officer, effective April 26, 2021. McCombs, with over 20 years of experience in medical device innovation, previously led R&D for BD's Medical Segment. Her role will focus on driving the company's innovation strategy and managing R&D efforts. Additionally, BD has established a new Scientific Advisory Board to enhance its innovation pipeline, with John DeFord as co-chair following his retirement on May 28, 2021.
The Board of Directors of BD (Becton, Dickinson and Company) has announced a quarterly dividend of $0.83 per common share, payable on June 30, 2021 to shareholders on record as of June 9, 2021. This indicates an annual dividend rate of $3.32 per share, reflecting the company's commitment to returning value to its investors.
On April 27, 2021, CerTest Biotec and BD (Becton, Dickinson and Company) announced that the VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR Detection Kit can now detect COVID-19 using saliva specimens on the BD MAX™ Molecular Diagnostic System. This addition enhances testing flexibility, allowing for nasopharyngeal, oropharyngeal, and saliva sample collection. The kit is CE marked and capable of detecting all known SARS-CoV-2 variants, essential for managing the ongoing pandemic in Europe.
BD (Becton, Dickinson and Company) has submitted a 510(k) premarket notification to the U.S. FDA for its BD Alaris™ System, a widely used infusion pump in U.S. hospitals. The submission aims to update regulatory clearance, implement new features, and address existing recall issues. The new software version will enhance clinical, operational, and cybersecurity aspects. BD emphasizes this submission as a pivotal step in their commitment to healthcare improvement. However, the FDA review process includes risks and there is no guarantee of clearance or specific timing.